Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial.

Saved in:
Bibliographic Details
Title: Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial.
Authors: Konstantinopoulos PA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA. Panagiotis_konstantinopoulos@dfci.harvard.edu., Zhou N; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA., Penson RT; Department of Medical Oncology, Massachusetts General Hospital, Boston, MA, 02114, USA., Le TV; Department of Oncology, Johns Hopkins University School of Medicine and Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, USA., Campos S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA., Krasner C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA., Wright AA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA., Porter R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA., Horowitz N; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA., Bouberhan S; Department of Medical Oncology, Massachusetts General Hospital, Boston, MA, 02114, USA., Liu JF; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA., Hindenach S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA., Sawyer H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA., Koppermann L; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA., Hayes M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA., Polak M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA., Shea M; Department of Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA, 02215, USA., Widick P; Department of Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA, 02215, USA., Cheng SC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA., Castro C; Department of Medical Oncology, Massachusetts General Hospital, Boston, MA, 02114, USA., Beumer JH; Department of Oncology, Johns Hopkins University School of Medicine and Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, USA., Matulonis UA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA., Lee EK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
Source: Nature communications [Nat Commun] 2025 Dec 03; Vol. 17 (1), pp. 395. Date of Electronic Publication: 2025 Dec 03.
Publication Type: Journal Article; Clinical Trial, Phase II
Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2041-1723
DOI:10.1038/s41467-025-67087-8